Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “theCompany”), is pleased to inform that EOC Pharma (“EOC”) and Immutep jointly discussed the current AIPAC results and confirmed plans to continue advancing Efti (designated as EOC202 in China) in metastatic breast cancer.
For more information, please download the attached PDF
Download this document
